Zenith Capital (Zenith Capital) EV-to-EBITDA : (As of May. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zenith Capital's enterprise value is $14.37 Mil. Zenith Capital does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Zenith Capital's EV-to-EBITDA at this moment.

The historical rank and industry rank for Zenith Capital's EV-to-EBITDA or its related term are showing as below:

ZHCLF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.41 Med: 0 Max: 0
Current: -2.27

ZHCLF's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.97 vs ZHCLF: -2.27

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Zenith Capital's stock price is $0.10. Zenith Capital does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Zenith Capital's PE Ratio at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Zenith Capital EV-to-EBITDA Historical Data

The historical data trend for Zenith Capital's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EV-to-EBITDA Chart

Zenith Capital Annual Data

Trend

EV-to-EBITDA

Zenith Capital Quarterly Data

EV-to-EBITDA

Competitive Comparison of Zenith Capital's EV-to-EBITDA

For the Biotechnology subindustry, Zenith Capital's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zenith Capital's EV-to-EBITDA falls into.

Zenith Capital EV-to-EBITDA Calculation

Zenith Capital's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	14.366	/
	=

Zenith Capital (OTCPK:ZHCLF) EV-to-EBITDA Explanation

Zenith Capital's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.10	/
	=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Zenith Capital EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines